Project Grant R01CA301616
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $646K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19107, USA
Similar Awards
- Federal Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $484,405 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2030. This five-year award supports fundamental cancer biology research investigating NSD2 (Nuclear Set Domain Family Member 2) mutations and their role in driving acute lymphoblastic leukemia (ALL) transformation. The research...
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $401,115 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period August 1, 2025, through July 31, 2027. The award funds research to develop and validate contrast-enhanced ultrasound (CEUS) as a diagnostic tool for evaluating hepatocellular carcinoma (HCC) treatment response following transarterial...
- Federal Project Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $1.66 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on March 6, 2026, with a completion date of February 28, 2031. This five-year award funds fundamental research to advance understanding of neuroendocrine prostate cancer (NEPC) progression and identify novel therapeutic vulnerabilities. The research program...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $1,998,484 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2026 and concluding August 31, 2029. The award funds a three-year research initiative titled "Deciphering the Role of PIK3CA Mutations in Tumorigenesis of HER2-Positive Breast Cancer," to be conducted at the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $144,193 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 4, 2025, with a completion date of August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath, a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, to advance research in cancer detection and treatment technologies. Dr. Korangath will...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2028. The award supports fundamental research to decipher mechanisms of resistance to anti-TROP2 antibody-drug conjugate (ADC) cancer therapy, specifically investigating why some patients develop resistance to sacituzumab govitecan (SG), an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $162,080 under the Cancer Research Manpower program (CFDA 93.398) on December 27, 2025, with a completion date of June 30, 2028. Dr. Komatsu's laboratory is conducting research to visualize and characterize B cell infiltration and aggregation within the tumor microenvironment, with particular focus on the role of high endothelial venules (HEVs) as critical gateways for...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a Project Grant of $426,828 under the Cancer Treatment Research program (CFDA 93.395) on May 4, 2026, with a completion date of April 30, 2028. This research grant supports the validation and translation of findings regarding JUMONJI KDM5 histone demethylase enzymes and their role in mediating resistance to CDK4/6 inhibitors in estrogen receptor-positive (ER+) breast...
- Federal Grant Award Summary Saint Joseph's University received a $420,600 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025, through August 31, 2028. This three-year research award supports mechanistic studies investigating the role of GABA Type A ion channel (GABAAR) receptors in triple-negative breast cancer (TNBC). The project employs a multidisciplinary approach combining expertise in GABAAR signaling...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...